MARKET

FOLD

FOLD

Amicus Therapeut
NASDAQ
9.90
-0.05
-0.50%
After Hours: 9.99 +0.09 +0.91% 18:28 12/05 EST
OPEN
9.96
PREV CLOSE
9.95
HIGH
10.05
LOW
9.79
VOLUME
3.68M
TURNOVER
--
52 WEEK HIGH
10.57
52 WEEK LOW
5.51
MARKET CAP
3.05B
P/E (TTM)
-215.6863
1D
5D
1M
3M
1Y
5Y
1D
Surging Earnings Estimates Signal Upside for Amicus Therapeutics (FOLD) Stock
NASDAQ · 16h ago
Can Galafold Continue to Drive Amicus' Top Line in 2026?
NASDAQ · 19h ago
BMY Gains on News of Continuation of Alzheimer's Disease Study
NASDAQ · 1d ago
Amicus Therapeutics CEO Bradley L. Campbell Reports Disposal of Common Shares
Reuters · 2d ago
BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business
NASDAQ · 3d ago
Weekly Report: what happened at FOLD last week (1124-1128)?
Weekly Report · 5d ago
Amicus Therapeutics Chief Development Officer Jeff Castelli Reports Disposal of Common Shares
Reuters · 11/27 02:19
Amicus Therapeutics Chief People Officer David Michael Clark Reports Sale of Common Shares
Reuters · 11/27 02:18
More
About FOLD
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.

Webull offers Amicus Therapeutics, Inc. stock information, including NASDAQ: FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FOLD stock methods without spending real money on the virtual paper trading platform.